Zynerba Pharmaceuticals, Inc
ZYNE
ZYNE was delisted on the 10th of October, 2023.
64 hedge funds and large institutions have $48.9M invested in Zynerba Pharmaceuticals, Inc in 2017 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 24 increasing their positions, 15 reducing their positions, and 17 closing their positions.
60% more capital invested
Capital invested by funds: $30.5M → $48.9M (+$18.4M)
60% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 15
11% more call options, than puts
Call options by funds: $2.57M | Put options by funds: $2.32M
4% less funds holding
Funds holding: 67 → 64 (-3)
12% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 17
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.95M |
| 2 |
Morgan Stanley
New York
|
+$1.8M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.17M |
| 4 |
HighTower Advisors
Chicago,
Illinois
|
+$956K |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
+$687K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$1.32M |
| 2 |
GPCM
Granite Point Capital Management
Boston,
Massachusetts
|
-$1.15M |
| 3 |
ARTA
A.R.T. Advisors
New York
|
-$792K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$512K |
| 5 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$473K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BA
76
Bristlecone Advisors
Bellevue,
Washington
| – | -$6K | -672 | Closed |
|
|
NFG
77
Next Financial Group
Houston,
Texas
| – | -$6K | -650 | Closed |
|
78
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
| – | -$2K | -199 | Closed |
|
|
PA
79
Parallel Advisors
San Francisco,
California
| – | -$1K | -120 | Closed |
|
|
CCMW
80
Cypress Capital Management (Wyoming)
Sheridan,
Wyoming
| – | -$1K | -100 | Closed |
|
|
STA
81
Summit Trail Advisors
New York
| – | +$287 | +25 | New |
|
ZYNE Hedge Fund Activity: Q4 2017 in Review
64 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Zynerba Pharmaceuticals, Inc (ZYNE) for Q4 2017, worth a combined $48.9M — up 60% from $30.5M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of ZYNE and 15 opened new positions — a net loss of 2 holders — while 15 trimmed existing stakes and 24 added.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $1.95M. The largest seller was Perceptive Advisors, exiting entirely with an estimated $1.32M sold.
- 64 institutional investors held Zynerba Pharmaceuticals, Inc (ZYNE) as of Q4 2017, down from 67 in Q3 2017.
- Funds reported $48.9M of Zynerba Pharmaceuticals, Inc stock for Q4 2017, up 60% quarter-over-quarter.
- 15 funds opened new Zynerba Pharmaceuticals, Inc positions in Q4 2017 and 17 closed out, a net change of -2 holders.
- The largest Zynerba Pharmaceuticals, Inc buyer in Q4 2017 was Susquehanna International Group, an estimated $1.95M added.
- The largest Zynerba Pharmaceuticals, Inc seller in Q4 2017 was Perceptive Advisors, an estimated $1.32M sold.
Based on aggregated 13F filings for Q4 2017.